Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

N.Y. AG Spitzer Criticizes FDA "Silence" On Disclosing Rx Trial Data

This article was originally published in The Pink Sheet Daily

Executive Summary

In a speech at the National Press Club, Eliot Spitzer discusses his lawsuit against GlaxoSmithKline that resulted in a settlement in which the company will publicly disclose clinical trial data. He says FDA "has not said a word" that would require other drug manufacturers to do the same.

You may also be interested in...



Forest Settles With Spitzer, Will Post All Phase III-IV Results On-Line

Forest Labs has agreed to post summaries of all Phase III and Phase IV trials on the Internet to resolve an investigation into the company by New York Attorney General Eliot Spitzer

GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005

The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel